Peloton Therapeutics

General Information


We are a clinical stage biopharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. We are initially targeting HIF-2α, a transcription factor which was previously thought to be intractable using a small molecule. We are a leader in the field of HIF-2α biology and pioneered the first HIF-2α inhibitor drug candidate to enter into clinical development. Our lead drug candidate, PT2977, has shown clinical proof of concept in patients with advanced or metastatic clear cell renal cell carcinoma (“mRCC”), and we plan to initiate patient enrollment in an international Phase 3 clinical trial in previously treated mRCC patients in the second half of 2019. PT2977 is also in a Phase 2 clinical trial in patients with von Hippel-Lindau disease (“VHL disease”) associated renal cell carcinoma (“RCC”) in the United States and Europe.

Employees: 64
Founded: 2010
Contact Information
Address 2330 Inwood Road, Suite 226, Dallas, TX 75235, US
Phone Number (972) 629-4100.
Web Address
View Prospectus: Peloton Therapeutics
Financial Information
Market Cap $711.4mil
Revenues $0 mil (last 12 months)
Net Income $-38.0 mil (last 12 months)
IPO Profile
Symbol PLTX
Exchange NASDAQ
Shares (millions): 9.4
Price range $15.00 - $17.00
Est. $ Volume $150.0 mil
Manager / Joint Managers J.P. Morgan/ Citigroup/ Jefferies
CO-Managers -
Expected To Trade: 5/23/2019
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change